The Experts below are selected from a list of 219 Experts worldwide ranked by ideXlab platform
Gordon B. Cutler - One of the best experts on this subject based on the ideXlab platform.
-
flutamide Testolactone and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia
The Journal of Clinical Endocrinology and Metabolism, 2000Co-Authors: Deborah P. Merke, Janet Jones, Suvimol Hill, Margaret F Keil, Jeremy D Fields, Gordon B. CutlerAbstract:Treatment outcome in congenital adrenal hyperplasia is often sub-optimal due to hyperandrogenism, treatment-induced hypercortisolism, or both. We previously reported better control of linear growth, weight gain, and bone maturation in a short term cross-over study of a new four-drug treatment regimen containing an antiandrogen (flutamide), an inhibitor of androgen to estrogen conversion (Testolactone), reduced hydrocortisone dose, and fludrocortisone, compared to the effects of a control regimen of hydrocortisone and fludrocortisone. Twenty-eight children have completed 2 yr of follow-up in a subsequent long term randomized parallel study comparing these two treatment regimens. During 2 yr of therapy, compared to children receiving hydrocortisone, and fludrocortisone treatment, children receiving flutamide, Testolactone, reduced hydrocortisone dose (average of 8.7 +/- 0.6 mg/m2 x day), and fludrocortisone had significantly (P < or = 0.05) higher plasma 17-hydroxyprogesterone, androstenedione, dehydroepiandrosterone, dehydroepiandrosterone sulfate, and testosterone levels. Despite elevated androgen levels, children receiving the new treatment regimen had normal linear growth rate (at 2 yr, 0.1 +/- 0.5 SD units), and bone maturation (at 2 yr, 0.7 +/- 0.3 yr bone age/yr chronological age). No significant adverse effects were observed after 2 yr. We conclude that the regimen of flutamide, Testolactone, reduced hydrocortisone dose, and fludrocortisone provides effective control of congenital adrenal hyperplasia with reduced risk of glucocorticoid excess. A long term study of this new regimen is ongoing.
-
Six-Year Results of Spironolactone and Testolactone Treatment of Familial Male-Limited Precocious Puberty with Addition of Deslorelin after Central Puberty Onset
The Journal of clinical endocrinology and metabolism, 1999Co-Authors: Ellen W. Leschek, Kevin M. Barnes, Janet Jones, Suvimol Hill, Gordon B. CutlerAbstract:Short term treatment with spironolactone, Testolactone, and, after the onset of central puberty, deslorelin can normalize the rate of growth and bone maturation in boys with familial male-limited precocious puberty. To test the hypothesis that this treatment can achieve long term normalization of the growth and development of these children, we examined the growth rate, bone maturation rate (change in bone age/change in chronological age), and predicted adult height of 10 boys who were treated with spironolactone (5.7 mg/kg x day) and Testolactone (40 mg/kg x day) for at least 6 yr. Deslorelin (4 microg/kg x day) treatment was initiated 2.6 +/- 1.3 yr after beginning spironolactone and Testolactone treatment. The growth rate normalized within 1 yr of starting treatment and remained normal during the next 5 yr of treatment (P < 0.001). The rate of bone maturation normalized during the second year of treatment and remained normal thereafter (P < 0.001). Predicted height increased from 160.7 +/- 14.7 centimeters at baseline to 173.6 +/- 10.1 centimeters after 6 yr of treatment (P < 0.05 during the fourth through the sixth year of treatment compared to baseline). We conclude that long term treatment with spironolactone, Testolactone, and, after central puberty, deslorelin normalizes the growth rate and bone maturation and improves the predicted height in boys with familial male-limited precocious puberty. The ultimate effect of this approach on adult height will require further study.
-
A preliminary study of flutamide, Testolactone, and reduced hydrocortisone dose in the treatment of congenital adrenal hyperplasia.
The Journal of clinical endocrinology and metabolism, 1996Co-Authors: Louisa Laue, Kevin M. Barnes, Deborah P. Merke, Janet Jones, Suvimol Hill, Gordon B. CutlerAbstract:Treatment outcome in congenital adrenal hyperplasia is often suboptimal due to hyperandrogenism, treatment-induced hypercortisolism, or both. As a new approach, we hypothesized that the effects of androgen could be blocked by an antiandrogen (flutamide) and an inhibitor androgen to estrogen conversion (Testolactone), thus allowing the hydrocortisone dose to be reduced. We conducted a short term pilot study in 12 children with congenital adrenal hyperplasia in a randomised cross-over open design to determine whether flutamide, Testolactone, reduced hydrocortisone dose, and fludrocortisone are more effective than hydrocortisone and fludrocortisone treatment in normalizing linear growth, weight gain, and bone maturation. Each regimen was administered for 6 months, with a 3-month washout period, consisting of hydrocortisone and fludrocortisone treatment, between regimens. Compared to hydrocortisone and fludrocortisone treatment, the regimen of flutamide, Testolactone, reduced hydrocortisone dose (from 12.9 to...
-
long term treatment of familial male precocious puberty fmpp with spironolactone Testolactone and deslorelin 536
Pediatric Research, 1996Co-Authors: Ellen W. Leschek, Kevin M. Barnes, Janet Jones, Suvimol Hill, Gordon B. CutlerAbstract:We have shown previously that short-term treatment with spironolactone (S), Testolactone (T), and, after onset of central puberty, deslorelin (D) can normalize the rate of growth and bone maturation in boys with FMPP. To test the hypothesis that this treatment can achieve long-term normalization of the growth and development of these children, we examined the growth rate, bone maturation rate (ΔBA/ΔCA), and predicted adult height of 7 boys who were treated with S (5.7 mg/kg/day) and T (40 mg/kg/day) for at least 6 years. The mean duration of symptoms prior to treatment was 1.6 ± 0.7 years, and the mean advancement of bone age at treatment onset was 3.6± 2.8 years. D (4 mcg/kg/day) treatment was initiated at 3.0 ± 1.2 years after beginning S and T. The long-term growth results are shown in the Table:
-
LONG-TERM TREATMENT OF FAMILIAL MALE PRECOCIOUS PUBERTY (FMPP) WITH SPIRONOLACTONE, Testolactone, AND DESLORELIN. † 536
Pediatric Research, 1996Co-Authors: Ellen W. Leschek, Kevin M. Barnes, Janet Jones, Suvimol Hill, Gordon B. CutlerAbstract:We have shown previously that short-term treatment with spironolactone (S), Testolactone (T), and, after onset of central puberty, deslorelin (D) can normalize the rate of growth and bone maturation in boys with FMPP. To test the hypothesis that this treatment can achieve long-term normalization of the growth and development of these children, we examined the growth rate, bone maturation rate (ΔBA/ΔCA), and predicted adult height of 7 boys who were treated with S (5.7 mg/kg/day) and T (40 mg/kg/day) for at least 6 years. The mean duration of symptoms prior to treatment was 1.6 ± 0.7 years, and the mean advancement of bone age at treatment onset was 3.6± 2.8 years. D (4 mcg/kg/day) treatment was initiated at 3.0 ± 1.2 years after beginning S and T. The long-term growth results are shown in the Table:
Janet Jones - One of the best experts on this subject based on the ideXlab platform.
-
flutamide Testolactone and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia
The Journal of Clinical Endocrinology and Metabolism, 2000Co-Authors: Deborah P. Merke, Janet Jones, Suvimol Hill, Margaret F Keil, Jeremy D Fields, Gordon B. CutlerAbstract:Treatment outcome in congenital adrenal hyperplasia is often sub-optimal due to hyperandrogenism, treatment-induced hypercortisolism, or both. We previously reported better control of linear growth, weight gain, and bone maturation in a short term cross-over study of a new four-drug treatment regimen containing an antiandrogen (flutamide), an inhibitor of androgen to estrogen conversion (Testolactone), reduced hydrocortisone dose, and fludrocortisone, compared to the effects of a control regimen of hydrocortisone and fludrocortisone. Twenty-eight children have completed 2 yr of follow-up in a subsequent long term randomized parallel study comparing these two treatment regimens. During 2 yr of therapy, compared to children receiving hydrocortisone, and fludrocortisone treatment, children receiving flutamide, Testolactone, reduced hydrocortisone dose (average of 8.7 +/- 0.6 mg/m2 x day), and fludrocortisone had significantly (P < or = 0.05) higher plasma 17-hydroxyprogesterone, androstenedione, dehydroepiandrosterone, dehydroepiandrosterone sulfate, and testosterone levels. Despite elevated androgen levels, children receiving the new treatment regimen had normal linear growth rate (at 2 yr, 0.1 +/- 0.5 SD units), and bone maturation (at 2 yr, 0.7 +/- 0.3 yr bone age/yr chronological age). No significant adverse effects were observed after 2 yr. We conclude that the regimen of flutamide, Testolactone, reduced hydrocortisone dose, and fludrocortisone provides effective control of congenital adrenal hyperplasia with reduced risk of glucocorticoid excess. A long term study of this new regimen is ongoing.
-
Six-Year Results of Spironolactone and Testolactone Treatment of Familial Male-Limited Precocious Puberty with Addition of Deslorelin after Central Puberty Onset
The Journal of clinical endocrinology and metabolism, 1999Co-Authors: Ellen W. Leschek, Kevin M. Barnes, Janet Jones, Suvimol Hill, Gordon B. CutlerAbstract:Short term treatment with spironolactone, Testolactone, and, after the onset of central puberty, deslorelin can normalize the rate of growth and bone maturation in boys with familial male-limited precocious puberty. To test the hypothesis that this treatment can achieve long term normalization of the growth and development of these children, we examined the growth rate, bone maturation rate (change in bone age/change in chronological age), and predicted adult height of 10 boys who were treated with spironolactone (5.7 mg/kg x day) and Testolactone (40 mg/kg x day) for at least 6 yr. Deslorelin (4 microg/kg x day) treatment was initiated 2.6 +/- 1.3 yr after beginning spironolactone and Testolactone treatment. The growth rate normalized within 1 yr of starting treatment and remained normal during the next 5 yr of treatment (P < 0.001). The rate of bone maturation normalized during the second year of treatment and remained normal thereafter (P < 0.001). Predicted height increased from 160.7 +/- 14.7 centimeters at baseline to 173.6 +/- 10.1 centimeters after 6 yr of treatment (P < 0.05 during the fourth through the sixth year of treatment compared to baseline). We conclude that long term treatment with spironolactone, Testolactone, and, after central puberty, deslorelin normalizes the growth rate and bone maturation and improves the predicted height in boys with familial male-limited precocious puberty. The ultimate effect of this approach on adult height will require further study.
-
A preliminary study of flutamide, Testolactone, and reduced hydrocortisone dose in the treatment of congenital adrenal hyperplasia.
The Journal of clinical endocrinology and metabolism, 1996Co-Authors: Louisa Laue, Kevin M. Barnes, Deborah P. Merke, Janet Jones, Suvimol Hill, Gordon B. CutlerAbstract:Treatment outcome in congenital adrenal hyperplasia is often suboptimal due to hyperandrogenism, treatment-induced hypercortisolism, or both. As a new approach, we hypothesized that the effects of androgen could be blocked by an antiandrogen (flutamide) and an inhibitor androgen to estrogen conversion (Testolactone), thus allowing the hydrocortisone dose to be reduced. We conducted a short term pilot study in 12 children with congenital adrenal hyperplasia in a randomised cross-over open design to determine whether flutamide, Testolactone, reduced hydrocortisone dose, and fludrocortisone are more effective than hydrocortisone and fludrocortisone treatment in normalizing linear growth, weight gain, and bone maturation. Each regimen was administered for 6 months, with a 3-month washout period, consisting of hydrocortisone and fludrocortisone treatment, between regimens. Compared to hydrocortisone and fludrocortisone treatment, the regimen of flutamide, Testolactone, reduced hydrocortisone dose (from 12.9 to...
-
long term treatment of familial male precocious puberty fmpp with spironolactone Testolactone and deslorelin 536
Pediatric Research, 1996Co-Authors: Ellen W. Leschek, Kevin M. Barnes, Janet Jones, Suvimol Hill, Gordon B. CutlerAbstract:We have shown previously that short-term treatment with spironolactone (S), Testolactone (T), and, after onset of central puberty, deslorelin (D) can normalize the rate of growth and bone maturation in boys with FMPP. To test the hypothesis that this treatment can achieve long-term normalization of the growth and development of these children, we examined the growth rate, bone maturation rate (ΔBA/ΔCA), and predicted adult height of 7 boys who were treated with S (5.7 mg/kg/day) and T (40 mg/kg/day) for at least 6 years. The mean duration of symptoms prior to treatment was 1.6 ± 0.7 years, and the mean advancement of bone age at treatment onset was 3.6± 2.8 years. D (4 mcg/kg/day) treatment was initiated at 3.0 ± 1.2 years after beginning S and T. The long-term growth results are shown in the Table:
-
LONG-TERM TREATMENT OF FAMILIAL MALE PRECOCIOUS PUBERTY (FMPP) WITH SPIRONOLACTONE, Testolactone, AND DESLORELIN. † 536
Pediatric Research, 1996Co-Authors: Ellen W. Leschek, Kevin M. Barnes, Janet Jones, Suvimol Hill, Gordon B. CutlerAbstract:We have shown previously that short-term treatment with spironolactone (S), Testolactone (T), and, after onset of central puberty, deslorelin (D) can normalize the rate of growth and bone maturation in boys with FMPP. To test the hypothesis that this treatment can achieve long-term normalization of the growth and development of these children, we examined the growth rate, bone maturation rate (ΔBA/ΔCA), and predicted adult height of 7 boys who were treated with S (5.7 mg/kg/day) and T (40 mg/kg/day) for at least 6 years. The mean duration of symptoms prior to treatment was 1.6 ± 0.7 years, and the mean advancement of bone age at treatment onset was 3.6± 2.8 years. D (4 mcg/kg/day) treatment was initiated at 3.0 ± 1.2 years after beginning S and T. The long-term growth results are shown in the Table:
Kevin M. Barnes - One of the best experts on this subject based on the ideXlab platform.
-
Six-Year Results of Spironolactone and Testolactone Treatment of Familial Male-Limited Precocious Puberty with Addition of Deslorelin after Central Puberty Onset
The Journal of clinical endocrinology and metabolism, 1999Co-Authors: Ellen W. Leschek, Kevin M. Barnes, Janet Jones, Suvimol Hill, Gordon B. CutlerAbstract:Short term treatment with spironolactone, Testolactone, and, after the onset of central puberty, deslorelin can normalize the rate of growth and bone maturation in boys with familial male-limited precocious puberty. To test the hypothesis that this treatment can achieve long term normalization of the growth and development of these children, we examined the growth rate, bone maturation rate (change in bone age/change in chronological age), and predicted adult height of 10 boys who were treated with spironolactone (5.7 mg/kg x day) and Testolactone (40 mg/kg x day) for at least 6 yr. Deslorelin (4 microg/kg x day) treatment was initiated 2.6 +/- 1.3 yr after beginning spironolactone and Testolactone treatment. The growth rate normalized within 1 yr of starting treatment and remained normal during the next 5 yr of treatment (P < 0.001). The rate of bone maturation normalized during the second year of treatment and remained normal thereafter (P < 0.001). Predicted height increased from 160.7 +/- 14.7 centimeters at baseline to 173.6 +/- 10.1 centimeters after 6 yr of treatment (P < 0.05 during the fourth through the sixth year of treatment compared to baseline). We conclude that long term treatment with spironolactone, Testolactone, and, after central puberty, deslorelin normalizes the growth rate and bone maturation and improves the predicted height in boys with familial male-limited precocious puberty. The ultimate effect of this approach on adult height will require further study.
-
A preliminary study of flutamide, Testolactone, and reduced hydrocortisone dose in the treatment of congenital adrenal hyperplasia.
The Journal of clinical endocrinology and metabolism, 1996Co-Authors: Louisa Laue, Kevin M. Barnes, Deborah P. Merke, Janet Jones, Suvimol Hill, Gordon B. CutlerAbstract:Treatment outcome in congenital adrenal hyperplasia is often suboptimal due to hyperandrogenism, treatment-induced hypercortisolism, or both. As a new approach, we hypothesized that the effects of androgen could be blocked by an antiandrogen (flutamide) and an inhibitor androgen to estrogen conversion (Testolactone), thus allowing the hydrocortisone dose to be reduced. We conducted a short term pilot study in 12 children with congenital adrenal hyperplasia in a randomised cross-over open design to determine whether flutamide, Testolactone, reduced hydrocortisone dose, and fludrocortisone are more effective than hydrocortisone and fludrocortisone treatment in normalizing linear growth, weight gain, and bone maturation. Each regimen was administered for 6 months, with a 3-month washout period, consisting of hydrocortisone and fludrocortisone treatment, between regimens. Compared to hydrocortisone and fludrocortisone treatment, the regimen of flutamide, Testolactone, reduced hydrocortisone dose (from 12.9 to...
-
long term treatment of familial male precocious puberty fmpp with spironolactone Testolactone and deslorelin 536
Pediatric Research, 1996Co-Authors: Ellen W. Leschek, Kevin M. Barnes, Janet Jones, Suvimol Hill, Gordon B. CutlerAbstract:We have shown previously that short-term treatment with spironolactone (S), Testolactone (T), and, after onset of central puberty, deslorelin (D) can normalize the rate of growth and bone maturation in boys with FMPP. To test the hypothesis that this treatment can achieve long-term normalization of the growth and development of these children, we examined the growth rate, bone maturation rate (ΔBA/ΔCA), and predicted adult height of 7 boys who were treated with S (5.7 mg/kg/day) and T (40 mg/kg/day) for at least 6 years. The mean duration of symptoms prior to treatment was 1.6 ± 0.7 years, and the mean advancement of bone age at treatment onset was 3.6± 2.8 years. D (4 mcg/kg/day) treatment was initiated at 3.0 ± 1.2 years after beginning S and T. The long-term growth results are shown in the Table:
-
LONG-TERM TREATMENT OF FAMILIAL MALE PRECOCIOUS PUBERTY (FMPP) WITH SPIRONOLACTONE, Testolactone, AND DESLORELIN. † 536
Pediatric Research, 1996Co-Authors: Ellen W. Leschek, Kevin M. Barnes, Janet Jones, Suvimol Hill, Gordon B. CutlerAbstract:We have shown previously that short-term treatment with spironolactone (S), Testolactone (T), and, after onset of central puberty, deslorelin (D) can normalize the rate of growth and bone maturation in boys with FMPP. To test the hypothesis that this treatment can achieve long-term normalization of the growth and development of these children, we examined the growth rate, bone maturation rate (ΔBA/ΔCA), and predicted adult height of 7 boys who were treated with S (5.7 mg/kg/day) and T (40 mg/kg/day) for at least 6 years. The mean duration of symptoms prior to treatment was 1.6 ± 0.7 years, and the mean advancement of bone age at treatment onset was 3.6± 2.8 years. D (4 mcg/kg/day) treatment was initiated at 3.0 ± 1.2 years after beginning S and T. The long-term growth results are shown in the Table:
-
Treatment of familial male precocious puberty with spironolactone, Testolactone, and deslorelin
The Journal of clinical endocrinology and metabolism, 1993Co-Authors: Louisa Laue, Kevin M. Barnes, Janet Jones, Gordon B. CutlerAbstract:Combined antiandrogen (spironolactone) and aromatase inhibitor (Testolactone) are effective for the short term treatment of familial male precocious puberty. During this therapy, plasma testosterone levels remain in the adult range, since spironolactone blocks the testosterone receptor without significantly affecting plasma testosterone levels. After our initial 18-month pilot study, we continued to treat eight boys with the combined therapy for 2.0-4.2 yr. During this time all boys exhibited a pubertal rise in gonadotropin secretion and a diminishing response to treatment, which was manifested by the recurrence of clinical features of puberty and an increase in the bone maturation rate (P < 0.05). Addition of the LHRH agonist deslorelin (4 micrograms/kg.day, sc) to the combined therapy decreased peak LH, plasma testosterone, bone maturation rate, and growth velocity (P < 0.05) over the next year. We conclude that the rise in gonadotropin levels during central activation of hypothalamic LHRH secretion in ...
Suvimol Hill - One of the best experts on this subject based on the ideXlab platform.
-
flutamide Testolactone and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia
The Journal of Clinical Endocrinology and Metabolism, 2000Co-Authors: Deborah P. Merke, Janet Jones, Suvimol Hill, Margaret F Keil, Jeremy D Fields, Gordon B. CutlerAbstract:Treatment outcome in congenital adrenal hyperplasia is often sub-optimal due to hyperandrogenism, treatment-induced hypercortisolism, or both. We previously reported better control of linear growth, weight gain, and bone maturation in a short term cross-over study of a new four-drug treatment regimen containing an antiandrogen (flutamide), an inhibitor of androgen to estrogen conversion (Testolactone), reduced hydrocortisone dose, and fludrocortisone, compared to the effects of a control regimen of hydrocortisone and fludrocortisone. Twenty-eight children have completed 2 yr of follow-up in a subsequent long term randomized parallel study comparing these two treatment regimens. During 2 yr of therapy, compared to children receiving hydrocortisone, and fludrocortisone treatment, children receiving flutamide, Testolactone, reduced hydrocortisone dose (average of 8.7 +/- 0.6 mg/m2 x day), and fludrocortisone had significantly (P < or = 0.05) higher plasma 17-hydroxyprogesterone, androstenedione, dehydroepiandrosterone, dehydroepiandrosterone sulfate, and testosterone levels. Despite elevated androgen levels, children receiving the new treatment regimen had normal linear growth rate (at 2 yr, 0.1 +/- 0.5 SD units), and bone maturation (at 2 yr, 0.7 +/- 0.3 yr bone age/yr chronological age). No significant adverse effects were observed after 2 yr. We conclude that the regimen of flutamide, Testolactone, reduced hydrocortisone dose, and fludrocortisone provides effective control of congenital adrenal hyperplasia with reduced risk of glucocorticoid excess. A long term study of this new regimen is ongoing.
-
Six-Year Results of Spironolactone and Testolactone Treatment of Familial Male-Limited Precocious Puberty with Addition of Deslorelin after Central Puberty Onset
The Journal of clinical endocrinology and metabolism, 1999Co-Authors: Ellen W. Leschek, Kevin M. Barnes, Janet Jones, Suvimol Hill, Gordon B. CutlerAbstract:Short term treatment with spironolactone, Testolactone, and, after the onset of central puberty, deslorelin can normalize the rate of growth and bone maturation in boys with familial male-limited precocious puberty. To test the hypothesis that this treatment can achieve long term normalization of the growth and development of these children, we examined the growth rate, bone maturation rate (change in bone age/change in chronological age), and predicted adult height of 10 boys who were treated with spironolactone (5.7 mg/kg x day) and Testolactone (40 mg/kg x day) for at least 6 yr. Deslorelin (4 microg/kg x day) treatment was initiated 2.6 +/- 1.3 yr after beginning spironolactone and Testolactone treatment. The growth rate normalized within 1 yr of starting treatment and remained normal during the next 5 yr of treatment (P < 0.001). The rate of bone maturation normalized during the second year of treatment and remained normal thereafter (P < 0.001). Predicted height increased from 160.7 +/- 14.7 centimeters at baseline to 173.6 +/- 10.1 centimeters after 6 yr of treatment (P < 0.05 during the fourth through the sixth year of treatment compared to baseline). We conclude that long term treatment with spironolactone, Testolactone, and, after central puberty, deslorelin normalizes the growth rate and bone maturation and improves the predicted height in boys with familial male-limited precocious puberty. The ultimate effect of this approach on adult height will require further study.
-
A preliminary study of flutamide, Testolactone, and reduced hydrocortisone dose in the treatment of congenital adrenal hyperplasia.
The Journal of clinical endocrinology and metabolism, 1996Co-Authors: Louisa Laue, Kevin M. Barnes, Deborah P. Merke, Janet Jones, Suvimol Hill, Gordon B. CutlerAbstract:Treatment outcome in congenital adrenal hyperplasia is often suboptimal due to hyperandrogenism, treatment-induced hypercortisolism, or both. As a new approach, we hypothesized that the effects of androgen could be blocked by an antiandrogen (flutamide) and an inhibitor androgen to estrogen conversion (Testolactone), thus allowing the hydrocortisone dose to be reduced. We conducted a short term pilot study in 12 children with congenital adrenal hyperplasia in a randomised cross-over open design to determine whether flutamide, Testolactone, reduced hydrocortisone dose, and fludrocortisone are more effective than hydrocortisone and fludrocortisone treatment in normalizing linear growth, weight gain, and bone maturation. Each regimen was administered for 6 months, with a 3-month washout period, consisting of hydrocortisone and fludrocortisone treatment, between regimens. Compared to hydrocortisone and fludrocortisone treatment, the regimen of flutamide, Testolactone, reduced hydrocortisone dose (from 12.9 to...
-
long term treatment of familial male precocious puberty fmpp with spironolactone Testolactone and deslorelin 536
Pediatric Research, 1996Co-Authors: Ellen W. Leschek, Kevin M. Barnes, Janet Jones, Suvimol Hill, Gordon B. CutlerAbstract:We have shown previously that short-term treatment with spironolactone (S), Testolactone (T), and, after onset of central puberty, deslorelin (D) can normalize the rate of growth and bone maturation in boys with FMPP. To test the hypothesis that this treatment can achieve long-term normalization of the growth and development of these children, we examined the growth rate, bone maturation rate (ΔBA/ΔCA), and predicted adult height of 7 boys who were treated with S (5.7 mg/kg/day) and T (40 mg/kg/day) for at least 6 years. The mean duration of symptoms prior to treatment was 1.6 ± 0.7 years, and the mean advancement of bone age at treatment onset was 3.6± 2.8 years. D (4 mcg/kg/day) treatment was initiated at 3.0 ± 1.2 years after beginning S and T. The long-term growth results are shown in the Table:
-
LONG-TERM TREATMENT OF FAMILIAL MALE PRECOCIOUS PUBERTY (FMPP) WITH SPIRONOLACTONE, Testolactone, AND DESLORELIN. † 536
Pediatric Research, 1996Co-Authors: Ellen W. Leschek, Kevin M. Barnes, Janet Jones, Suvimol Hill, Gordon B. CutlerAbstract:We have shown previously that short-term treatment with spironolactone (S), Testolactone (T), and, after onset of central puberty, deslorelin (D) can normalize the rate of growth and bone maturation in boys with FMPP. To test the hypothesis that this treatment can achieve long-term normalization of the growth and development of these children, we examined the growth rate, bone maturation rate (ΔBA/ΔCA), and predicted adult height of 7 boys who were treated with S (5.7 mg/kg/day) and T (40 mg/kg/day) for at least 6 years. The mean duration of symptoms prior to treatment was 1.6 ± 0.7 years, and the mean advancement of bone age at treatment onset was 3.6± 2.8 years. D (4 mcg/kg/day) treatment was initiated at 3.0 ± 1.2 years after beginning S and T. The long-term growth results are shown in the Table:
Ellen W. Leschek - One of the best experts on this subject based on the ideXlab platform.
-
Six-Year Results of Spironolactone and Testolactone Treatment of Familial Male-Limited Precocious Puberty with Addition of Deslorelin after Central Puberty Onset
The Journal of clinical endocrinology and metabolism, 1999Co-Authors: Ellen W. Leschek, Kevin M. Barnes, Janet Jones, Suvimol Hill, Gordon B. CutlerAbstract:Short term treatment with spironolactone, Testolactone, and, after the onset of central puberty, deslorelin can normalize the rate of growth and bone maturation in boys with familial male-limited precocious puberty. To test the hypothesis that this treatment can achieve long term normalization of the growth and development of these children, we examined the growth rate, bone maturation rate (change in bone age/change in chronological age), and predicted adult height of 10 boys who were treated with spironolactone (5.7 mg/kg x day) and Testolactone (40 mg/kg x day) for at least 6 yr. Deslorelin (4 microg/kg x day) treatment was initiated 2.6 +/- 1.3 yr after beginning spironolactone and Testolactone treatment. The growth rate normalized within 1 yr of starting treatment and remained normal during the next 5 yr of treatment (P < 0.001). The rate of bone maturation normalized during the second year of treatment and remained normal thereafter (P < 0.001). Predicted height increased from 160.7 +/- 14.7 centimeters at baseline to 173.6 +/- 10.1 centimeters after 6 yr of treatment (P < 0.05 during the fourth through the sixth year of treatment compared to baseline). We conclude that long term treatment with spironolactone, Testolactone, and, after central puberty, deslorelin normalizes the growth rate and bone maturation and improves the predicted height in boys with familial male-limited precocious puberty. The ultimate effect of this approach on adult height will require further study.
-
long term treatment of familial male precocious puberty fmpp with spironolactone Testolactone and deslorelin 536
Pediatric Research, 1996Co-Authors: Ellen W. Leschek, Kevin M. Barnes, Janet Jones, Suvimol Hill, Gordon B. CutlerAbstract:We have shown previously that short-term treatment with spironolactone (S), Testolactone (T), and, after onset of central puberty, deslorelin (D) can normalize the rate of growth and bone maturation in boys with FMPP. To test the hypothesis that this treatment can achieve long-term normalization of the growth and development of these children, we examined the growth rate, bone maturation rate (ΔBA/ΔCA), and predicted adult height of 7 boys who were treated with S (5.7 mg/kg/day) and T (40 mg/kg/day) for at least 6 years. The mean duration of symptoms prior to treatment was 1.6 ± 0.7 years, and the mean advancement of bone age at treatment onset was 3.6± 2.8 years. D (4 mcg/kg/day) treatment was initiated at 3.0 ± 1.2 years after beginning S and T. The long-term growth results are shown in the Table:
-
LONG-TERM TREATMENT OF FAMILIAL MALE PRECOCIOUS PUBERTY (FMPP) WITH SPIRONOLACTONE, Testolactone, AND DESLORELIN. † 536
Pediatric Research, 1996Co-Authors: Ellen W. Leschek, Kevin M. Barnes, Janet Jones, Suvimol Hill, Gordon B. CutlerAbstract:We have shown previously that short-term treatment with spironolactone (S), Testolactone (T), and, after onset of central puberty, deslorelin (D) can normalize the rate of growth and bone maturation in boys with FMPP. To test the hypothesis that this treatment can achieve long-term normalization of the growth and development of these children, we examined the growth rate, bone maturation rate (ΔBA/ΔCA), and predicted adult height of 7 boys who were treated with S (5.7 mg/kg/day) and T (40 mg/kg/day) for at least 6 years. The mean duration of symptoms prior to treatment was 1.6 ± 0.7 years, and the mean advancement of bone age at treatment onset was 3.6± 2.8 years. D (4 mcg/kg/day) treatment was initiated at 3.0 ± 1.2 years after beginning S and T. The long-term growth results are shown in the Table: